New First-Line Treatment for Stage III-IV High Grade Ovarian Serous Cancers (HGOSC)

Precision Oncology specialist, Alex Rolland, discusses a new first-line treatment for Stage III-IV High Grade Ovarian Serous Cancers (HGOSC).
He explains the unprecedented results of a recent study - the DUO-O/ENGOT-ov46/GOG-3025 Trial - which showed longer PFS (Progression-Free Survival) rates than ever before with this particular cancer type and stage! Alex also shares the key takeaways that high-grade ovarian serous cancer patients need to know about this new treatment combination protocol.
He is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They also share next steps to take to find out if this new protocol will work for you and how to access it.
00:00 Introduction
00:16 Alex’s Presentation: New First-Line Treatment for Stage III-IV High Grade Ovarian Serous Cancers
02:05 Standard care for Stage III-IV High Grade Ovarian Serous Cancers (HGOSC)
03:06 Exploring the DUO-O/ENGOT-ov46/GOG-3025 Trial
04:11 Introducing immune therapy drug, Durvalumab (Imfinzi)
04:35 Introducing Parp Inhibitor, Olaparib (Lynparza)
05:49 Analysis of the PFS rates (Progression-Free Survival)
08:00 Chart illustrating genes involved with deficient HR Status
11:19 Further suggestions for patients with HGOSC
12:20 How to tell if you have HRD and if you will benefit from this new combination
13:21 How to get the information and support you need now
Learn more about the tumour testing required to match you to this treatment: • Why Tumor DNA Sequenci...
If you’d like to identify the most effective treatment for your cancer, and how to access it as soon as possible (and through your current treatment team) reach out to us and book a free 30-min consult using the link below 👇
Book a Free Session With Alex And His Precision Oncology Team: www.ctoam.com/free-strategy-s...
Download CTOAM’S Free Ebook Here: www.ctoam.com/ebook/
Join our (free) "Cancer Just the Facts" online program!
👉 cancerjustthefacts.com/
Get hundreds of free resources on Precision Cancer Medicine and access to our weekly Zoom calls with cancer experts.
-
CTOAM is a worldwide, Canadian-based personalized cancer care and precision oncology service specializing in getting our client's rapid access to the best possible cancer treatment available for their form of cancer, while assisting their physicians in having the most current data from which to make confident treatment decisions on your behalf.
We facilitate access to peer-reviewed, science-based precision diagnostics such as PET/CT scans, liquid biopsy (blood-based genetic tests) and detailed genetic panels. We use these leading diagnostic tools, combined with a thorough and personalized research review, as our team explores the most advanced scientific data available today to find the best options for you.
Other ways to stay in touch with CTOAM:
Facebook: / cancertreatmentoptions...
LinkedIn: / ctoam
Twitter: / ctoam
Blog: research.ctoam.com/
LinkedIn (Liquid Biopsy Labs): / 13063544
LBL Twitter: / liquidbiopsynow
Disclaimer:
Please understand that these videos are meant for educational purposes only. These videos are not intended to diagnose or be used as treatment advice. Viewers are encouraged to speak with their doctor or healthcare professionals for medical advice and before making any changes to their healthcare based on this information. All statements made in this video regarding medical treatments and health conditions are sourced and have been approved by the U.S. Food and Drug Administration (FDA). Watching this video is not a substitute for professional medical advice or a diagnosis.

[@darlenelucentini1725]

I am a young Italian patient and I am pursuing the second degree in biological sciences with cellular and molecular address. I have high grade 3 stage serous ovarian cancer with brca1 mutation. I am on olaparib and for now I am fine, I am NED, but due to the studies I do I know many things and I am terrified by the recurrence of disease. I would like to add durvalumab to my therapy but in Italy it is not prescribed. How can I do it? I would like some extra chances, I don’t want to end up in hospice so young to wait for death for months. Could you help me? Thank you so much

[@user-ms9mu4mb1t]

My friend who had stage 3 ovarian cancer is HRD negative. She been standard treated (chemo, surgery and chemo). Is Niraparib is suitable for her as maintenance therapy? Is there any other available therapy for her? She is in Ottawa.

[@ikecat1755]

Hello as far as I know, the PARP inhibitors are only currently approved for use in BRCA 1 & 2 mutations or HRD status after frontline treatment. The PARP inhibitor Lynparza has been used in trials on women who are not BRCA or HRD, with some success…but to my knowledge, it is not approved for use in this population. I wonder if Avastin infusions every 3 weeks for as long as it can be tolerated would be a good choice for her?

[@tonydionnegulotta2715]

Why is it always first line treatment, what about the rest of us who have bern fighting this horrid disease for yrs. We need new treatment to help us to. We need new treatment to help us survive. This is so unfair for. I’m BRCA1. Nothing is working anymore. I need new treatment but can’t get anything because it’s always for frontline. Again so unfair, so the rest of us have to die because there’s no new treatment for the rest of us because we aren't frontline.

[@ikecat1755]

Agreed Tony! I do think that these studies eventually filter out to the recurrent OC population, and maybe that will be the case for this new combination therapy that has been so promising for Frontline treatment. It seems like for recurrent OC (for BRCA one and two negative gals), the only option is eternal Avastin, which you eventually have to stop suddenly because of unacceptable protein levels, or recurrence… Then face the rebound aspects of this drug. Good luck, and keep the faith!